{
  "image_filename": "table_p7_det_6_004.png",
  "image_path": "Hsiao_et_al.__2023_/extracted/figures/table_p7_det_6_004.png",
  "image_type": "Table",
  "page_number": 7,
  "block_id": "det_6_004",
  "claim_id": "claim_007",
  "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
  "supports_claim": false,
  "explanation": "A table of participant demographic and clinical characteristics (age groups, sex, race/ethnicity, underlying illnesses, prior influenza vaccination) for cohorts receiving recombinant vaccine versus standard-dose egg-derived vaccine. does not support the claim: the table only presents baseline demographic and clinical characteristics of study participants and contains no immunogenicity or antibody response data comparing broadly cross-reactive antibody levels between recombinant BEVS-derived and egg-derived vaccines.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table of participant demographic and clinical characteristics (age groups, sex, race/ethnicity, underlying illnesses, prior influenza vaccination) for cohorts receiving recombinant vaccine versus standard-dose egg-derived vaccine.",
    "evidence_found": null,
    "reasoning": "does not support the claim: the table only presents baseline demographic and clinical characteristics of study participants and contains no immunogenicity or antibody response data comparing broadly cross-reactive antibody levels between recombinant BEVS-derived and egg-derived vaccines.",
    "confidence_notes": null
  }
}